Pfizer and BioNTech have requested U.S. regulators to extend the emergency use authorization (US) for the Covid-19 vaccine on Friday to expand its use in the United States. Adolescents between 12 and 15 years old.
As reported in a statement, the two companies plan to require other companies to make similar resolutions. Regulatory agencies around the world In the following days, as the European Medicines Agency (EMA).
These requirements are based on key Phase 3 trial data for adolescents aged 12-15 (with or without prior evidence of SARS-CoV-2 infection). 100% efficiency After receiving the Covid-19 vaccine, the antibody response was strong.
In this analysis, the vaccine is Well tolerated Side effects are generally consistent with those seen by participants between 16 and 25 years of age.
All trial participants will remain controlled After the second use, it can provide more than two years of long-term protection and safety.